The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years to 75 Years
- Sex
- All sexes
- Healthy volunteers
- Accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
This research study wants to learn about Chronic Kidney Disease (CKD) with Obesity, and Heart Failure with preserved Ejection Fraction (HFpEF) and better ways to evaluate these diseases. HFpEF means that the heart is not able to fill properly with blood while it is resting so the amount of blood pumped out to the body is less than it would be if it was filling properly. The study is being done to describe the differences in how the kidneys handle protein and salt in participants with HFpEF and obesity compared to healthy persons.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Criteria for Cohort 1: Healthy Participants Inclusion Criteria: * Adults 18-75 years old * Normal kidney function * No heart failure * BMI 25-30kg/m2 Exclusion Criteria: * Diagnosis of chronic illness * eGFR\<60mL/min/1.73m2 * Pregnancy or breast feeding * History of cutaneous or allergic reaction to iodine-based products of contrast dyes * Hemoglobin levels \<7mg/dL * Acute illness or hospitalization event within 3 months * Unable to stop NSAIDs * Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism * Current use of nicotine or recreational drugs, chronic drinker Criteria for Cohort 2: Obese Participants without HFpEF Inclusion Criteria: * Adults 18-75 years old * eGFR \>= 60 mL/min/1.73m2 * BMI \> 35 kg/m2 Exclusion Criteria: * Diagnosis of Heart Failure * Diagnosis of chronic illness * eGFR\<60mL/min/1.73m2 * Pregnancy or breast feeding * History of cutaneous or allergic reaction to iodine-based products of contrast dyes * Hemoglobin levels \<7mg/dL * Acute illness or hospitalization event within 3 months * Unable to stop NSAIDs * Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism * Current use of nicotine or recreational drugs, chronic drinker Criteria for Cohort 3: HFpEF and Obese Participants Inclusion Criteria: * Adults 18-75 years old * eGFR \>= 60 mL/min/1.73m2 * BMI \> 35 kg/m2 * Diagnosis of HFpEF (chart diagnosis, LVEF \> 55% on echo, H2FPEF score 6-9 or HFA-PEFF score 5 or 6 Exclusion Criteria: * NYHA class III/IV * Urinary retention screen + * Mobility issues * History of RRT or kidney transplant * Acute illness/hospitalization in the past 3 months * History of cancer, chemo, or XRT * Pregnant/breastfeeding * History of allergies to contrast * Hemoglobin \< 7 * Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism * Unable to stop NSAIDs * Current use of nicotine or recreational drugs, chronic drinker
Study sites (1)
MS
- University of Mississippi Medical Center · Jackson, MS 39216Tekka Johnson · Study contact · 601-496-7834 · tjohnson23@umc.eduMarissa C Tio, MD · Principal investigatorMore trials in Jackson